Related Experiment Video

Updated: May 13, 2026

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
06:12

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Published on: March 3, 2023

Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history

Masashi Furukawa1, Junichi Soh, Hiromasa Yamamoto

  • 1Department of Thoracic Surgery, Okayama University Hospital, Okayama 700-8558, Japan.

Acta Medica Okayama
|February 27, 2013
PubMed

Insights

The tumor suppressor gene NFKBIA (Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α) is often silenced in lung adenocarcinomas. This study found NFKBIA silencing occurs independently of common EGFR/K-ras mutations or EML4-ALK fusions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α (NFKBIA) functions as a tumor suppressor.
  • NFKBIA silencing has been observed in lung adenocarcinomas.
  • The relationship between NFKBIA expression and common genetic alterations in lung adenocarcinoma is not fully understood.

Purpose of the Study:

  • To investigate the expression of NFKBIA in lung adenocarcinoma samples from never-smokers.
  • To determine the correlation between NFKBIA expression and mutations in EGFR and K-ras genes, as well as EML4-ALK fusion.
  • To explore the potential role of NFKBIA silencing in lung adenocarcinoma carcinogenesis independent of known driver mutations.

Main Methods:

  • Analysis of NFKBIA expression using immunohistochemistry in 101 resected lung adenocarcinoma samples.
  • Detection of EGFR and K-ras mutations and EML4-ALK fusion in the same patient cohort.
  • Statistical analysis to compare NFKBIA expression levels with the presence or absence of genetic alterations.

Main Results:

  • NFKBIA expression was negative in 15.8% of the lung adenocarcinoma samples.
  • EGFR mutations, K-ras mutations, and EML4-ALK fusion were detected in 60.5%, 1.0%, and 2.0% of samples, respectively, and occurred mutually exclusively.
  • Negative NFKBIA expression was significantly more frequent in tumors lacking EGFR/K-ras mutations or EML4-ALK fusion (p = 0.009) and in EGFR-wild type tumors (p = 0.013).

Conclusions:

  • NFKBIA expression is frequently silenced in lung adenocarcinomas, particularly those without EGFR/K-ras mutations or EML4-ALK fusion.
  • The silencing of NFKBIA may represent an alternative pathway in lung adenocarcinoma development, independent of common driver mutations.
  • Further research is warranted to elucidate the precise mechanisms and clinical implications of NFKBIA silencing in lung cancer.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...